Figure 4

NeuroHeal has a supra-additive neuroprotective effect and is effective upon oral administration. (A) Left, Bar graph of NSC-34 cell survival upon ER stress measured by MTT assay at different dose ratios of ACA (A; 1X = 0.22 mM) to RIB (R; 1X B = 4 µM). Right, Effect of range of doses within 0–2X with NeuroHeal or with single drugs at 1X (p < 0.05 with respect to TN alone). (B) Representative microphotographs of MNs stained by Nissl at the ipsilateral ventral horns of RA animals treated orally with either vehicle or dose 1 (0.22 mM ACA + 0.4 µM RIB) or dose 2 (0.06 mM ACA + 1 µM RIB), and bar graph of the percentage of surviving MN cells at the ipsilateral side with respect to the contralateral side. (n = 4). (C) Bar graph of average immunoreactivity intensity for GFAP, Iba1, and GAP43 in a fixed region of interest in the ipsilateral ventral horn in grey matter for GFAP and Iba1 staining or white matter for GAP43 (n = 4; *p < 0.05 vs. vehicle).